Quintet Private Bank Europe S.A. Sells 2,179 Shares of Eli Lilly and Company $LLY

Quintet Private Bank Europe S.A. lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 35,523 shares of the company's stock after selling 2,179 shares during the period. Eli Lilly and Company comprises 1.6% of Quintet Private Bank Europe S.A.'s holdings, making the stock its 20th largest holding. Quintet Private Bank Europe S.A.'s holdings in Eli Lilly and Company were worth $27,691,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of LLY. PNC Financial Services Group Inc. raised its stake in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after buying an additional 14,852,076 shares during the period. Nuveen LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $4,613,912,000. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Eli Lilly and Company by 15.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company's stock worth $5,469,527,000 after buying an additional 969,376 shares during the period. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gabrielle Sulzberger purchased 117 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last quarter. 0.13% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LLY. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target for the company. in a report on Sunday, August 17th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $941.35.

Eli Lilly and Company Stock Down 0.2%

Shares of NYSE LLY opened at $754.90 on Monday. The stock has a market capitalization of $714.48 billion, a P/E ratio of 49.34, a P/E/G ratio of 1.05 and a beta of 0.47. The company has a 50-day moving average price of $741.03 and a 200-day moving average price of $775.51. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $942.35. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the company earned $3.92 earnings per share. The business's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a dividend of $1.50 per share. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.